ADC Therapeutics expands by circa. 12,000 sq ft at Imperial College I-HUB Building

JLL acts for Imperial College as ADC Therapeutics grows its presence at I-HUB in White City. The oncology-focused biotechnology company has secured the eighth floor, which marks a significant expansion bringing ADC Therapeutic’s footprint at the campus to c.24,000 sq ft.

Located in White City, London’s thriving district, I-HUB supports knowledge-intensive companies through providing facilities and co-location, connecting businesses with Imperial’s world-leading academics.

I-HUB also provides businesses with access to talent, leading edge knowledge, multi-disciplinary expertise, technical capabilities and equipment and a space that fosters open collaboration and growth.

Paddy Shipp, Director – Head of UK Life Sciences Agency at JLL said, “We’ve seen good demand from life science companies choosing to take space in London and with White City being a key innovation hub in the city, this has received high levels of interest. ADC Therapeutics expanding their presence at the site is a vote of confidence for White City as a key life science cluster.”

Patrick van Berkel, PhD, Chief Scientific Officer at ADC Therapeutics commented, “We are excited to expand our research facilities at White City as we work to develop new therapies to treat patients with cancer who have limited treatment options. Our researchers appreciate the support of the team at I-HUB and we look forward to a continued partnership as we endeavour to make a difference in the lives of patients worldwide.”

John Anderson, Chief Investment Officer at Imperial College London added, “Seeing great companies grow at I-HUB is a mark of success that endorses the value of Imperial’s White City Campus and the White City Innovation District eco-system. “By supporting ADC Therapeutics strategic growth, we know that they will now accelerate discovery and that advances society.  That is at the heart of what I-HUB and the eco-system needs to do”.